trial · primary record
Pembrolizumab
Cervical Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1023 |
| Primary completion | 2031-10-29 |
| Primary endpoint | Part 1 Safety Run-in: Number of Participants Who Experience One or More Adverse Events (AEs) |
| Registry ID | NCT07216703 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:38.254Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07216703
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- PEMBROLIZUMAB · approval
- Pembrolizumab · compound